Muscarinic acetylcholine receptor (M3)

Assets acting on this target.

Class
Muscarinic M3 receptor antagonist (anticholinergic bronchodilator)
Pathway
blocks acetylcholine-mediated airway smooth-muscle contraction

The M3 muscarinic acetylcholine receptor is a G-protein-coupled receptor expressed on airway smooth muscle, submucosal glands, and other tissues. In the lungs, the neurotransmitter acetylcholine, released from vagal nerve endings, binds M3 receptors to trigger smooth-muscle contraction and mucus secretion. This cholinergic tone is a major contributor to airway narrowing in chronic obstructive pulmonary disease (COPD) and, to a lesser degree, asthma. Blocking M3 with an antagonist ('anticholinergic' or antimuscarinic agent) prevents acetylcholine from activating this contractile pathway, producing bronchodilation and reduced mucus output. Because acetylcholine also acts on a related subtype, M2, which normally provides negative feedback on its own release, effective bronchodilators are designed to act preferentially at M3 over M2 so as not to blunt this self-limiting mechanism. Antimuscarinic bronchodilators fall into short-acting and long-acting classes, distinguished largely by how quickly the drug dissociates from the receptor once bound; short-acting agents wash out relatively quickly, while long-acting ones remain bound for many hours, allowing once- or twice-daily dosing. This mechanism broadly matters wherever cholinergic-driven bronchoconstriction is a dominant feature of airway disease, and it complements other bronchodilator classes such as beta-agonists, which act through a distinct signaling pathway.

By indication

Related mechanisms

Muscarinic acetylcholine receptor (M3) drugs compared

11 drugs, stage by indication
11 drugs acting on Muscarinic acetylcholine receptor (M3): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Aclidinium bromideTudorza PressairAzurity Pharmaceuticalssmall moleculeApprovedApproved in Chronic Obstructive Pulmonary Disease
Aclidinium bromide/formoterol fumarateDuaklir PressairAlmirall, Azurity Pharmaceuticalssmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
fluticasone furoate/umeclidinium/vilanterolTrelegy ElliptaGlaxoSmithKlinesmall molecule combinationApprovedApproved in Asthma; Approved in Chronic Obstructive Pulmonary Disease
Glycopyrrolate/formoterol fumarateBevespi AerosphereAstraZenecasmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
IpratropiumBoehringer Ingelheimsmall moleculeApprovedApproved in Chronic Obstructive Pulmonary Disease; Phase 3 in Asthma
Olodaterol/tiotropium bromideBoehringer Ingelheimsmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
Tiotropium bromideBoehringer Ingelheimsmall moleculeApprovedApproved in Asthma; Approved in Chronic Obstructive Pulmonary Disease
UmeclidiniumIncruse ElliptaGlaxoSmithKlinesmall moleculeApprovedApproved in Chronic Obstructive Pulmonary Disease; Phase 2 in Asthma
Umeclidinium/VilanterolGlaxoSmithKline, Innoviva, Sino Biopharmaceuticalsmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
Oxitropium bromide (Ba253BINEB)Boehringer Ingelheimsmall moleculePhase 3Phase 3 in Asthma
Glycopyrronium (PT001)AstraZenecasmall moleculePhase 2/3Phase 2/3 in Asthma

← all mechanisms